Cell production rates in human tissues and tumours and their significance. Part 1: an introduction to the techniques of measurement and their limitations

被引:28
作者
Rew, DA
Wilson, GD
机构
[1] Southampton Univ Hosp, Southampton, Hants, England
[2] Mt Vernon Hosp, Canc Res Campaign, Gray Lab, Northwood HA6 2JR, Middx, England
来源
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY | 2000年 / 26卷 / 03期
关键词
cell proliferation; flow cytometry; prognosis; clinical outcome; bromodeoxyuridine; cancer;
D O I
10.1053/ejso.1999.0781
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the past two decades, the technology of laser cytometry and use of the halogenated thymidine (HP) analogues bromodeoxyuridine and iododeoxyuridine as proliferation labels, have allowed us to quantify the rate of cell turnover in tissues and tumours, in clinical samples as in laboratory models. The principal studies have used injection of bromo- or iododeoxyuridine to measure cell production rates in vivo. Flow cytometry (FCM) has been used to estimate the S phase labelling index (LI) and the S phase duration (Ts) and calculate the cell production rate, represented by the potential doubling time (Tpot), This has allowed calculation of time-dependent indices of proliferation from single biopsies of HP pulse labelled human tissues and tumours, In the first part of this two-part review, we describe the technique and its limitations as a biological assay. The second part summarizes the knowledge gained about cell production rates and the relevance that this information may have to future investigative, prognostic and treatment strategies.
引用
收藏
页码:227 / 238
页数:12
相关论文
共 69 条
[31]   ALTERED CTP SYNTHETASE-ACTIVITY CONFERS RESISTANCE TO 5-BROMODEOXYURIDINE TOXICITY AND MUTAGENESIS [J].
KAUFMAN, ER .
MUTATION RESEARCH, 1986, 161 (01) :19-27
[32]   CONTINUOUS INTRAVENOUS INFUSIONS OF BROMODEOXYURIDINE AS A CLINICAL RADIOSENSITIZER [J].
KINSELLA, TJ ;
MITCHELL, JB ;
RUSSO, A ;
AIKEN, M ;
MORSTYN, G ;
HSU, SM ;
ROWLAND, J ;
GLATSTEIN, E .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (10) :1144-1150
[33]   IN-VIVO LABELING WITH HALOGENATED PYRIMIDINES OF SQUAMOUS-CELL CARCINOMAS AND ADJACENT NONINVOLVED MUCOSA OF HEAD AND NECK REGION [J].
KOTELNIKOV, VM ;
COON, JS ;
TAYLOR, S ;
HUTCHINSON, J ;
PANJE, W ;
CALDARELLI, DD ;
LAFOLLETTE, S ;
PREISLER, HD .
CELL PROLIFERATION, 1995, 28 (09) :497-509
[34]   DYNAMICS OF TUMOR GROWTH [J].
LAIRD, AK .
BRITISH JOURNAL OF CANCER, 1964, 18 (03) :490-&
[35]   Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas [J].
Langford, LA ;
Cooksley, CS ;
DeMonte, F .
HUMAN PATHOLOGY, 1996, 27 (04) :350-354
[36]   PROLIFERATION OF HUMAN RENAL-CELL CARCINOMA STUDIED WITH IN-VIVO IODODEOXYURIDINE LABELING AND IMMUNOHISTOCHEMISTRY [J].
LARSSON, P ;
ROOS, G ;
STENLING, R ;
LJUNGBERG, B .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1994, 28 (02) :135-140
[37]   IN-VITRO BROMODEOXYURIDINE LABELING OF MALIGNANT NEOPLASMS - A COMPARATIVE-STUDY WITH FLOW-CYTOMETRY CELL-CYCLE ANALYSIS [J].
LLOVERAS, B ;
GARINCHESA, P ;
MYC, A ;
MELAMED, M .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1994, 101 (06) :703-707
[38]   Iododeoxyuridine labelling of S-phase fraction in fine needle aspirates from breast carcinomas [J].
Maas, RA ;
Bruning, PF ;
Breedijk, AJ ;
Peterse, JL .
JOURNAL OF CLINICAL PATHOLOGY, 1996, 49 (07) :607-609
[39]  
MEYER JS, 1993, CANCER, V71, P3531, DOI 10.1002/1097-0142(19930601)71:11<3531::AID-CNCR2820711112>3.0.CO
[40]  
2-0